Dg Capital Management, LLC Fennec Pharmaceuticals Inc. Transaction History

Dg Capital Management, LLC

$162 Million
Q1 2024

A detailed history of Dg Capital Management, LLC transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Dg Capital Management, LLC holds 1,511,663 shares of FENC stock, worth $9.24 Million. This represents 10.39% of its overall portfolio holdings.

Number of Shares

1,511,663

Previous 1,075,634 40.54%

Holding current value

$9.24 Million

Previous $12.1 Million 39.29%

% of portfolio

10.39%

Previous 7.83%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$8.82 - $11.12 $3.85 Million - $4.85 Million	436,029 Added 40.54%	1,511,663 $16.8 Million
Q4 2023 Feb 12, 2024	SELL	$6.48 - $11.61 $437,173 - $783,268	-67,465 Reduced 5.9%	1,075,634 $12.1 Million
Q3 2023 Nov 14, 2023	BUY	$7.15 - $8.94 $489,381 - $611,898	68,445 Added 6.37%	1,143,099 $8.58 Million
Q2 2023 Aug 11, 2023	SELL	$7.27 - $9.82 $1.28 Million - $1.72 Million	-175,442 Reduced 14.03%	1,074,654 $9.49 Million
Q1 2023 May 11, 2023	BUY	$7.38 - $10.35 $1.68 Million - $2.36 Million	228,144 Added 22.32%	1,250,096 $10.4 Million

Q4 2022 Feb 13, 2023	BUY	$7.91 - $10.22 $133,291 - $172,217	16,851 Added 1.68%	1,021,952 $9.81 Million
Q3 2022 Nov 14, 2022	SELL	$5.71 - $8.54 $1.17 Million - $1.76 Million	-205,537 Reduced 16.98%	1,005,101 $8.14 Million
Q1 2022 May 11, 2022	BUY	$4.29 - $6.08 $219,858 - $311,593	51,249 Added 4.42%	1,210,638 $6.78 Million
Q4 2021 Feb 14, 2022	BUY	$3.89 - $10.01 $2.1 Million - $5.41 Million	540,938 Added 87.47%	1,159,389 $5.1 Million
Q3 2021 Nov 12, 2021	BUY	$6.51 - $9.62 $193,203 - $285,502	29,678 Added 5.04%	618,451 $5.83 Million
Q2 2021 Aug 12, 2021	BUY	$5.96 - $7.85 $3.51 Million - $4.62 Million	588,773 New	588,773 $4.29 Million

Others Institutions Holding FENC

# of Institutions

Shares Held

14.4M

Call Options Held

53.2K

Put Options Held

83.9K

View Full List

About FENNEC PHARMACEUTICALS INC.

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $159M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

More about FENC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dg Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dg Capital Management, LLC with notifications on news.

Account

Dg Capital Management, LLC Fennec Pharmaceuticals Inc. Transaction History